Skip to main content
. 2016 Dec 16;17(12):2114. doi: 10.3390/ijms17122114

Figure 1.

Figure 1

Figure 1

Comparing chemical characteristics of ingredients in WDD versus metabolic syndrome (MS) drugs. (AE) are distributions of drug-like properties of ingredients in WDD and MS drugs; (F) chemical space distribution of WDD versus MS drugs by principal component analysis (PCA).